Junyuan Yang

Junyuan Yang

Auto-generated profile, based on publicly available information

Junyuan Yang

Beijing Institute of Technology, Beijing 100081, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in Science Advances
Verified
Journal Article
Open access
DWDong Wang
Dong Wang
JZJun Zhou
Jun Zhou
ZCZhixin Chen
Zhixin Chen
JYJunyuan Yang
Junyuan Yang
YLYingjie Li
Yingjie Li
MYMingzhu Yang
Mingzhu Yang
Primary aldosteronism (PA), a leading cause of secondary hypertension, remains vastly underdiagnosed due to unreliable screening tools. We developed an integrated platform combining a high-gradient magnetic separation three-dimensional (HGMS-3D) chip and locked nucleic acid (LNA)–enhanced droplet digital polymerase chain reaction (ddPCR) for noninvasive detection of potassium inwardly rectifying channel subfamily J member 5 ( KCNJ5 ) mutations in plasma small extracellular vesicles (sEVs). The HGMS-3D chip uses a nickel mesh–based stereoscopic immunoaffinity capture system, achieving a vesicle isolation efficiency 4.4-fold higher than ultracentrifugation. Coupled with LNA-ddPCR, the platform detects KCNJ5 hotspot mutations [p.Gly151Arg, (G151R); p.Leu168Arg (L168R)] at minor allele frequencies of ≤0.05% ( R 2 ≥ 0.99), overcoming plasma-derived noise. Clinical validation in 106 patients with PA demonstrated 64.58% sensitivity and 96.88% specificity for sEV-based mutation profiling. The assay identified one aldosterone-producing adenoma (APA) case missed by tissue genotyping, achieving area under the receiver operating characteristic curve (AUC) values of 0.767 ~ 0.852 across mutations. This noninvasive approach could enable curative treatment for millions with undiagnosed PA, advancing precision management of endocrine hypertension through sEV-based liquid biopsy.